BC
KRYS icon

Bayforest Capital’s Krystal Biotech KRYS Stock Holding History

Bayforest Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Buy
+106
New +$31.7K 0.04% 680

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bayforest Capital's KRYS Position: Q2 2026 in Review

Bayforest Capital opened a new position in Krystal Biotech (KRYS) in Q2 2026: 106 shares worth $39.4K. The stake represents 0.04% of the portfolio and ranks #680 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Bayforest Capital held 106 shares of Krystal Biotech worth $39.4K as of Q2 2026.
  • Krystal Biotech was a new Bayforest Capital position in Q2 2026.
  • Krystal Biotech made up 0.04% of Bayforest Capital's portfolio in Q2 2026, its #680 holding.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.